Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US10118968B2 · kind B2 · utility
2Cited by
56References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2009 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Dec 29, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.